Fluetizolam Pellets – 1mg
€ 20,00
Fluetizolam Pellets 1mg are described as compressed research pellets containing a nominal 1 mg of fluetizolam per unit.
Fluetizolam is identified in the supplied source as a thienotriazolodiazepine-related compound, structurally associated with the etizolam family.
The reported chemical information includes CAS number 40054-88-4, molecular formula C17H15FN4S, and molecular weight approximately 326.39 g/mol.
The CAS assignment and correspondence between the reported systematic name and molecular structure have not been independently verified.
The source claims ingredient purity of at least 98%, independent analytical testing, batch traceability, and finished-pellet content uniformity below 2% RSD.
No batch-specific Certificate of Analysis, assay, or content-uniformity dataset was supplied.
The nominal 1 mg label claim should not be treated as a verified quantitative measurement.
Fluetizolam is associated with benzodiazepine-class safety concerns, including sedation, impaired coordination, dependence, and potentially dangerous interactions with other central nervous system depressants.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Fluetizolam Pellets 1mg – Research Material Information
Fluetizolam Pellets 1mg – Product Overview
Fluetizolam Pellets 1mg is the supplied catalog designation for compressed research pellets described as containing fluetizolam.
The source specifies a nominal ingredient content of 1 mg per unit.
This is a label claim, not a verified finished-pellet assay.
The material is described as a thienotriazolodiazepine-related compound intended for controlled laboratory characterization.
No actual batch-specific Certificate of Analysis, pellet-content report, or independent analytical documentation was supplied.
The material is not established as a certified reference standard or approved pharmaceutical product.
Chemical Identity & Classification
The source identifies fluetizolam as a thienotriazolodiazepine-related compound.
The supplied specifications include:
- Reported chemical name: 4-(2-Fluorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine
- Reported CAS number: 40054-88-4
- Reported molecular formula: C17H15FN4S
- Reported molecular weight: Approximately 326.39 g/mol
- Reported form: Compressed pellets
- Nominal ingredient content: 1 mg per pellet
- Intended designation: Research Use Only
The molecular formula and reported molecular weight are approximately consistent.
However, their consistency does not independently establish the chemical identity of the material.
The CAS number, systematic name, and actual chemical form require confirmation against authoritative records.
Public chemical-reference information can be reviewed through PubChem, with attention to the exact chemical structure.
Chemical & Physical Characteristics
The source describes compressed pellets containing fluetizolam.
No actual product inspection report, pellet-dimension specification, hardness measurement, or disintegration record was supplied.
The source does not identify the pellet excipients or establish the physical form of the ingredient within the compressed matrix.
Solubility, thermal stability, and quantitative recovery are mentioned as analytical considerations.
However, no validated product-specific measurements were provided.
The source also does not establish the impurity profile or stability of the complete pellet formulation.
Purity & Analytical Verification
The source claims ingredient purity of at least 98% by HPLC.
It also refers to LC-MS and NMR identity confirmation.
No chromatogram, mass spectrum, NMR spectrum, impurity report, or batch-specific Certificate of Analysis was supplied.
The claimed purity therefore remains unverified.
Ingredient purity and finished-pellet content are different measurements.
A high-purity ingredient does not establish that each pellet contains exactly 1 mg of fluetizolam.
The source describes trace-level analytical contexts, but no validated quantitative reference value or certified reference-material documentation was supplied.
The pellets should not be described as certified analytical standards without appropriate supporting records.
Quality Control & Batch Integrity
The source claims independent laboratory testing, batch traceability, controlled production, and content uniformity below 2% relative standard deviation.
These claims are not supported by supplied batch-specific records.
No pellet-content dataset, manufacturing record, independent laboratory report, or validated uniformity study was provided.
Total pellet weight, ingredient purity, and actual ingredient content are distinct properties.
For low-content solid formulations, verified finished-unit assay and content uniformity are particularly important to any quantitative specification.
The Research Use Only designation does not independently establish validated quality or analytical performance.
Safety, Handling & Laboratory Precautions
Fluetizolam is associated with benzodiazepine-related central nervous system depressant hazards.
Potential risks include sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.
Combining benzodiazepine-related substances with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.
The source does not provide a verified product-specific Safety Data Sheet.
Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.
The pellet presentation does not imply suitability for human or animal administration.
Packaging, Labeling & Storage
The source describes resealable packaging containing compressed pellets.
No actual packaging specification or container-validation record was supplied.
The source recommends storage at approximately -20°C in a dry environment protected from light and moisture.
No validated finished-product stability study was provided to establish that temperature as a confirmed storage requirement.
The source does not establish a verified shelf life, packaging-protection performance, or long-term ingredient stability.
Laboratory inventory records should distinguish nominal product specifications from verified batch information.
Intended Research Use & Market Positioning
The source places fluetizolam within laboratory contexts involving thienotriazolodiazepine chemical identity, analytical characterization, and structural comparison.
No validated calibration performance or certified reference-material status has been demonstrated.
The supplied Raw Lab Chems catalog references include Fluclotizolam 0.5mg Pellets, Fluetizolam Pellets 1mg, and Flunitrazolam Blotters 0.25mg.
These listings refer to different chemical compounds or finished-product presentations.
Their identity, potency, formulation, and analytical performance should not be treated as interchangeable.
Catalog relationships do not establish certified analytical status or equivalent chemical properties.
Ordering, Availability & Fulfillment
The source claims international shipping, temperature-controlled transport, tracking, and customs documentation.
No current inventory record, carrier authorization, shipment documentation, or verified delivery information was supplied.
The source also characterizes the material as a Schedule I research chemical and claims IATA/DOT compliance.
Neither the asserted scheduling classification nor the transport-compliance claim has been independently verified.
Controlled-substance classifications depend on the jurisdiction and must not be generalized.
Research-only labeling does not establish an exemption from applicable law.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Fluetizolam is a benzodiazepine-related compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be restricted.
Institutions remain responsible for verifying applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.
No therapeutic approval, consumer-use authorization, or certified analytical status is implied.
| Quantity (pellets) |
25 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.